Video

Current Treatment Landscape for HER2+ Breast Cancer

Author(s):

Ruth O'Regan, MD, University of Rochester Medical CenterJoyce O'Shaugnessy, MD, Texas Oncology

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with HER2+ breast cancer.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Shipra Gandhi, MD
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Related Content
Sara M. Tolaney, MD, MPH
July 26th 2024

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lajos Pusztai, MD, DPhil
July 25th 2024

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Priscilla F. McAuliffe, MD, PhD, of UPMC Hillman Cancer Center
July 24th 2024

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

Adrienne G. Waks, MD
July 24th 2024

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line